Table 1.
Baseline and end of study values (mean ± SD) for the Multicenter Study of Hydroxyurea (MSH), which gave maximum tolerated dose, and the Ibadan study, which gave a fixed low-dose of 500 mg/day.
| MSH (N = 152) |
Ibadan (N = 48) |
P (com-parison of change between cohorts) | |||||
|---|---|---|---|---|---|---|---|
| Baseline | End of Study (104 weeks) | Change in mean value | Baseline | End of Study (24 weeks) | Change in mean value | ||
| Hemoglobin (g/L) | 8.5 ± 1.4 | 9.1 ± 1.5 | 0.6 | 7.8 ± 1.1 | 8.3 ± 1.1 | 0.5 | 0.7 |
| Hematocrit (%) | 24.9 ± 4.4 | 27.0 ± 5.0 | 2.1 | 24.9 ± 3.3 | 26.8 ± 3.5 | 1.9 | 0.8 |
| MCV (fL) | 94 ± 9 | 103 ± 14 | 9 | 86 ± 8 | 96 ± 10 | 10 | 0.7 |
| White blood cells (1000/μL) | 12.6 ± 3.4 | 9.9 ± 3.1 | -2.7 | 10.2 ± 2.4 | 9.2 ± 2.6 | -1.0 | 0.002 |
| Neutrophils (1000/μL) | 6.9 ± 2.4 | 4.9 ± 2.0 | -2.0 | 5.3 ± 1.5 | 4.8 ± 1.9 | -0.5 | <0.001 |
| Platelets (1000/μL) | 468 ± 147 | 399 ± 124 | -69 | 489 ± 186 | 397± 143 | -92 | 0.4 |
| Hemoglobin F (%) | 5.0 ± 3.5 | 8.6 ± 6.8 | 3.6 | 4.9 ± 3.0 | 8.9 ± 5.3 | 4.0* | 0.8 |
*
n=20